Skip to main content

Division of Aging Biology Funding Opportunity Announcements

DAB is currently seeking applications in response to funding opportunity announcements in the biology of aging and in geroscience. Please see below for active FAO developed by DAB or joined by DAB. DAB also seeks applications related to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) in some specific areas.

The full list of NIA-wide active funding opportunities and NIA-wide AD/ADRD funding opportunities can be found online. Read NIA's research and funding frequently asked questions.

The table below contains funding opportunity announcements that are currently being funded in full or in part by the Division of Aging Biology (DAB). The FOAs are grouped by RFA, PAR, then PA, and listed in ascending order of the expiration date.

Funding Opportunity Announcements
FOA Number Title Released Expires DAB Contact
RFA-AG-21-026 Preclinical Development of Novel Therapeutics Targeting Aging Mechanisms (SBIR U44 Clinical Trial Not Allowed) 25-Jun-20 11-Nov-20 Rebecca Fuldner, Ph.D
RFA-AG-21-003 New/Unconventional Animal Models of Alzheimers Disease (R24 Clinical Trial Not Allowed) 13-Jan-20 8-Oct-20 Manuel Moro, DVM, Ph.D
RFA-AG-20-035 Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed) 31-Jul-19 20-Oct-20 Ronald A. Kohanski, Ph.D

PAR-18-514

Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed) 20-Dec-17 06-Jan-21 Max Guo, Ph.D

PAR-18-512

Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed) 20-Dec-17 06-Jan-21 Max Guo, Ph.D
PAR-19-249 Environmental Influences on Aging-Effects of Extreme Weather and Disaster Events on Aging Processes (R01 Clinical Trial Not Allowed) 12-Apr-19 9-Mar-21 Ronald A. Kohanski, Ph.D
PAR-19-304 Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional) 25-Jun-19 17-Jul-22 Rebecca A. Fuldner, Ph.D
PAR-19-305 Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional) 25-Jun-19 17-Jul-22 Rebecca A. Fuldner, Ph.D

PA-18-572

Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional) 11-Jan-18 08-May-21 Candace L. Kerr, Ph.D

PA-18-571

Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional) 11-Jan-18 08-May-21 Candace L. Kerr, Ph.D

PA-18-570

Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional) 11-Jan-18 08-May-21 Candace L. Kerr, Ph.D

PA-18-738

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional). 3-Apr-18 8-May-21 Francesca Macchiarini, Ph.D

PA-18-739

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional). 3-Apr-18 8-May-21 Francesca Macchiarini, Ph.D